O

Orchestra Biomed Holdings Inc
NASDAQ:OBIO

Watchlist Manager
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Watchlist
Price: 4.08 USD -1.92%
Market Cap: $230.4m

Net Margin

-2 665%
Current
Declining
by 757.1%
vs 3-y average of -1 907.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 665%
=
Net Income
$-75.1m
/
Revenue
$2.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 665%
=
Net Income
$-75.1m
/
Revenue
$2.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
234.9m USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
187.5B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
185.6B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
139.4B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.7B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.6B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.6B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
54.9B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
47.9B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.5B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-2 665%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Orchestra Biomed Holdings Inc
Glance View

Market Cap
230.4m USD
Industry
Health Care

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.

OBIO Intrinsic Value
Not Available
O
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 665%
=
Net Income
$-75.1m
/
Revenue
$2.8m
What is Orchestra Biomed Holdings Inc's current Net Margin?

The current Net Margin for Orchestra Biomed Holdings Inc is -2 665%, which is below its 3-year median of -1 907.9%.

How has Net Margin changed over time?

Over the last 3 years, Orchestra Biomed Holdings Inc’s Net Margin has decreased from 159 650% to -2 665%. During this period, it reached a low of -2 672.2% on Jun 30, 2024 and a high of 159 650% on Sep 30, 2022.

Back to Top